Gardiner will oversee talent acquisition and HR operations during period of rapid company growth
VANCOUVER, BC, Canada – August 15, 2023 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced the appointment of Diane Gardiner as the company’s Chief Human Resources Officer. Gardiner joins Aspect during a high-growth period, and will focus on spearheading team expansion and development, optimizing HR operations, and continuing to foster a strong company culture.
“Aspect is one of the most exciting companies in the biotech space right now, with a rare combination of cutting-edge technology, truly diverse and interdisciplinary talent, and a bold mission to change the lives of people living with serious disease,” said Diane Gardiner, Chief Human Resources Officer at Aspect Biosystems. “I’m thrilled to join the team and help fuel Aspect’s growth during such a pivotal time for the company.”
Gardiner brings more than 30 years of experience in human resources, including executive-level roles in both private and public biotech companies, and has deep expertise in developing and deploying HR strategies in order to support rapid growth. She comes to Aspect from Sierra Oncology, which was acquired by GSK in 2022 for US$1.9 billion, where she served for eight years as Senior Vice President of Human Resources and Administration.
“Diane is a highly respected and creative HR leader in the biotech industry who has a proven track record of driving strategic, sustained growth,” said Tamer Mohamed, CEO of Aspect Biosystems. “As Chief Human Resources Officer, Diane will play a pivotal role in developing the HR processes, systems, and structures needed to scale and support our interdisciplinary team on our mission to develop innovative, functional cures for debilitating diseases.”
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases. Learn more at www.aspectbiosystems.com.
Contact
Emily Stearney
HDMZ
Aspect.PR@HDMZ.com